AstraZeneca and Kinaxo have entered into an agreement in which Kinaxo will employ its high-end mass spectrometry-based technologies to quantitatively analyze post-translational modifications (PTMs) in proteins on a proteome-wide scale in support of one of AstraZeneca’s oncology programs.
Kinaxo’s Cellular Target Profiling technology employs a combination of quantitative mass spectrometry and software applications to analyze proteome-wide PTM patterns in vivo. The platform provides insights into small molecule target interactions and binding affinities across the proteome of any given cell line or tissue sample, according to the firm. In addition, the compound’s protein targets are determined in a physiological context.